Continuing Education Courses
Continuing Education for MLS & MLT
Continuing Education for Phlebotomists
Continuing Education for Histologists
HR Courses
Intro to the Medical Lab
Video Continuing Education Courses
All Available Courses
Exam Simulators
Exam Simulator for MLS & MLT
NSH + LabCE Histology Exam Simulator
Phlebotomy Exam Simulator
Molecular Exam Simulator
Case Simulators
Bacteriology Case Simulator
Blood Bank Case Simulator
Blood Culture Gram Stain Case Simulator
Body Fluid Case Simulator
RBC Morphology Simulator
Urinalysis Case Simulator
White Blood Cell Differential Case Simulator
Advanced WBC Differential Case Simulator
LabCE Quiz Game
Contact & Support
Log In
Log In
ADP Receptor (P2Y12 Receptor) Inhibitors
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 183 CE courses, most popular
$109
Add to cart
Pick Your Courses
Up to 8 CE hours
$55
Add to cart
Individual course
$25
Add to cart
The page below is a sample from the LabCE course
Antiplatelet and Anticoagulant Pharmacology for the Laboratory Professional
. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.
Learn more about Antiplatelet and Anticoagulant Pharmacology for the Laboratory Professional (online CE course)
ADP Receptor (P2Y12 Receptor) Inhibitors
Examples:
Clopidogrel
,
prasugrel
,
ticagrelor
, and
ticlopidine
are drugs in the ADP receptor (also known as P2Y12 receptor) inhibitor class.
Mechanism of action:
As discussed earlier,
ADP
is a substance released from platelets that activate other platelets and results in platelet aggregation. The drugs of this class irreversibly inhibit the ADP receptor on platelets, making them unresponsive to ADP. This results in decreased platelet aggregation.
Use:
Ticlopidine
is used to prevent strokes in those unable to take
aspirin
;
clopidogrel
is also used to prevent thrombosis, particularly after a patient has coronary angioplasty to open an occluded coronary artery.
Laboratory measurement:
Like with
aspirin
, there are platelet aggregation tests that assess the ability of platelets to aggregate in vitro. A normal response to
clopidogrel
therapy (or therapy with the other drugs in this class) would be decreased platelet aggregation when a patient's platelets are exposed to platelet aggregation agonists. Genetic testing can be performed for CYP2C19, an enzyme involved in the metabolism of
clopidogrel
. This enzyme is needed to metabolize the ingested
clopidogrel
into its active form. This test may be ordered to determine if a patient who is not responding to
clopidogrel
testing has a genetic variant of the CYP2C19 enzyme.
Toxicity:
Ticlopidine
causes bone marrow suppression with neutropenia and thrombocytopenia, and the values for those analytes must be monitored.
Clopidogrel
produces gastrointestinal symptoms similar to
aspirin
and doesn't have the bone marrow suppression of
ticlopidine
.
X
×